ZA967732B - Pharmaceutical combination preparations containing erythropoietin and ferric complexes. - Google Patents

Pharmaceutical combination preparations containing erythropoietin and ferric complexes.

Info

Publication number
ZA967732B
ZA967732B ZA9607732A ZA967732A ZA967732B ZA 967732 B ZA967732 B ZA 967732B ZA 9607732 A ZA9607732 A ZA 9607732A ZA 967732 A ZA967732 A ZA 967732A ZA 967732 B ZA967732 B ZA 967732B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical combination
preparations containing
combination preparations
containing erythropoietin
ferric complexes
Prior art date
Application number
ZA9607732A
Other languages
English (en)
Inventor
Paul Lehmann
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of ZA967732B publication Critical patent/ZA967732B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA9607732A 1995-09-14 1996-09-13 Pharmaceutical combination preparations containing erythropoietin and ferric complexes. ZA967732B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19535571A DE19535571A1 (de) 1995-09-14 1995-09-14 Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten

Publications (1)

Publication Number Publication Date
ZA967732B true ZA967732B (en) 1998-03-13

Family

ID=7773098

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9607732A ZA967732B (en) 1995-09-14 1996-09-13 Pharmaceutical combination preparations containing erythropoietin and ferric complexes.

Country Status (26)

Country Link
US (2) US6333306B1 (cs)
EP (1) EP0851762B1 (cs)
JP (1) JP4783482B2 (cs)
KR (1) KR100350761B1 (cs)
CN (1) CN1133463C (cs)
AT (1) ATE216256T1 (cs)
AU (1) AU724623B2 (cs)
BR (1) BR9609971A (cs)
CA (1) CA2231192C (cs)
CZ (1) CZ291427B6 (cs)
DE (3) DE19535571A1 (cs)
DK (1) DK0851762T3 (cs)
EE (1) EE03856B1 (cs)
ES (1) ES2174107T3 (cs)
HU (1) HU225363B1 (cs)
IL (2) IL123640A0 (cs)
MX (1) MX9801922A (cs)
NO (1) NO329908B1 (cs)
NZ (1) NZ319132A (cs)
PL (1) PL186776B1 (cs)
PT (1) PT851762E (cs)
SK (1) SK285796B6 (cs)
TR (1) TR199800472T1 (cs)
UA (1) UA57713C2 (cs)
WO (1) WO1997009996A1 (cs)
ZA (1) ZA967732B (cs)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041226A1 (de) * 1997-03-18 1998-09-24 Roche Diagnostics Gmbh Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate
EP0885613A1 (de) * 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
DE19734293A1 (de) * 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
SI1813624T1 (sl) * 1998-10-23 2010-12-31 Amgen Inc Postopki in sestavki za prepeäśevanje in zdravljenje anemije
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
AU2002233230B2 (en) 2000-12-20 2007-02-01 F. Hoffmann-La Roche Ag Erythropoietin conjugates
EP1909106B1 (en) * 2001-09-14 2013-01-02 F. Hoffmann-La Roche AG Differential diagnosis of disorders of iron metabolism by means of four parameters and recommendations for the treatment of these disorders of iron metabolism
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US7300915B2 (en) * 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7964568B2 (en) * 2003-05-30 2011-06-21 Chromaceutical Advanced Technologies, Inc. Synthesis of high molecular weight iron-saccharidic complexes
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US7586589B2 (en) * 2005-09-24 2009-09-08 Beckman Coulter, Inc. Methods of determination of responsiveness to erythropoietin treatment
PT2054074E (pt) 2006-08-04 2014-11-07 Prolong Pharmaceuticals Llc Eritropoietina modificada
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
US11857543B2 (en) * 2013-06-13 2024-01-02 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
EP3789395A1 (en) 2015-11-23 2021-03-10 Bristol-Myers Squibb Company Pegylation of fgf21

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6039681B2 (ja) * 1976-01-01 1985-09-07 日本臓器製薬株式会社 デキストリン・クエン酸・第二鉄多核複合体及び該複合体を含有する非経口用鉄剤
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JPS6231A (ja) * 1985-02-06 1987-01-06 Chugai Pharmaceut Co Ltd 腎性貧血治療剤
NO881507D0 (no) * 1987-04-10 1988-04-07 Ortho Pharma Corp Fremgangsmaate for forhoeyning av hematokritnivaaet til et normalt pattedyr.

Also Published As

Publication number Publication date
PL325640A1 (en) 1998-08-03
KR19990044610A (ko) 1999-06-25
US20020049161A1 (en) 2002-04-25
NO981136D0 (no) 1998-03-13
ES2174107T3 (es) 2002-11-01
HUP9900357A2 (hu) 1999-05-28
CN1202113A (zh) 1998-12-16
SK285796B6 (sk) 2007-08-02
CA2231192A1 (en) 1997-03-20
WO1997009996A1 (de) 1997-03-20
PT851762E (pt) 2002-08-30
EE9800066A (et) 1998-08-17
CZ72698A3 (cs) 1998-07-15
EP0851762A1 (de) 1998-07-08
NO981136L (no) 1998-03-13
UA57713C2 (uk) 2003-07-15
JP4783482B2 (ja) 2011-09-28
NO329908B1 (no) 2011-01-24
TR199800472T1 (xx) 1998-06-22
JPH11512414A (ja) 1999-10-26
DE59609099D1 (de) 2002-05-23
DE19535571A1 (de) 1997-03-20
DE19680768D2 (de) 1998-11-05
CN1133463C (zh) 2004-01-07
EP0851762B1 (de) 2002-04-17
SK32798A3 (en) 1999-03-12
PL186776B1 (pl) 2004-02-27
AU7128296A (en) 1997-04-01
NZ319132A (en) 1999-09-29
US6333306B1 (en) 2001-12-25
HUP9900357A3 (en) 2001-04-28
CA2231192C (en) 2003-02-25
CZ291427B6 (cs) 2003-03-12
KR100350761B1 (ko) 2003-03-03
ATE216256T1 (de) 2002-05-15
MX9801922A (es) 1998-05-31
BR9609971A (pt) 1999-09-14
IL123640A0 (en) 1998-10-30
EE03856B1 (et) 2002-10-15
IL123640A (en) 2006-06-11
AU724623B2 (en) 2000-09-28
HU225363B1 (en) 2006-10-28
DK0851762T3 (da) 2002-08-12

Similar Documents

Publication Publication Date Title
ZA967732B (en) Pharmaceutical combination preparations containing erythropoietin and ferric complexes.
IL82209A0 (en) Insulin preparation
IL108528A0 (en) Pulmonary administration of epo
MX9707854A (es) Administracion pulmonar de alfa 1-antitripsina en forma de polvo seco.
CA2284910A1 (en) Pharmaceutical combined preparations containing erythropoietin and iron preparations
HUT58204A (en) Magnesium-pyridoxale-5'-phosphate-glutaminate for preventing diseases originated from blood-vessel-alternations
CA2060560A1 (en) Method for insuring adequate intracellular glutathione in tissue
CA2127107A1 (en) Methods and compositions for reducing blood loss
TWI263502B (en) Pharmaceutical preparation for treating ischemic disease of heart or limbs
NZ514629A (en) PEGylated interferon-alpha administered at about 4.5- 9.0 micrograms/kg/week as a renal cell carcinoma treatment
TR199902305T2 (xx) Eritropoitein ve demir preperasyonları içeren farmasötik birleşimli preperasyonlar.
GR3002381T3 (en) Use of a carboxylic acid in pharmaceutical preparations intended for topical application
UA19647A (uk) Спосіб лікуваhhя остеомієліту щелепи
UA10219A (uk) Спосіб лікування туберкульозу легень
HU9200147D0 (en) Medical preparations with human interleukin-2 content
IL98276A0 (en) Use of anaesthetic agents in the manufacture of pharmaceutical preparations for iontophoresis
BG94567A (en) Medicaments for the treatment of aids and method for its application
CA2159609A1 (en) Factor xiii for treatment of skin wounds
GB9017658D0 (en) Inhaler for social and medical use
ZA914000B (en) Use of local anaesthetic agents in the manufacture of pharmaceutical preparations for iontophoresis
GEU1999444Y (en) Medicinal Means “Barambo”